Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-01-04 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事关于《中源协和细胞基因工程股份有限公司未来三年（2018-2020年）股东分红回报规划》的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's future three-year shareholder dividend return plan (2018-2020). It references relevant laws and regulations and confirms the plan's compliance and benefits to shareholders. The document is short (857 characters) and does not contain financial statements or detailed financial data. It is a formal opinion related to a dividend plan but does not announce dividend amounts or payment dates. It is not a full report but an opinion on a plan that will be submitted to the shareholders' meeting. Therefore, it fits best as a Regulatory Filing (RNS) because it is a formal regulatory disclosure related to corporate governance and dividend planning but not a direct dividend announcement or a full report.
2018-01-04 Chinese
东兴证券股份有限公司关于公司股票价格波动是否达到《关于规范上市公司信息披露及相关各方行为的通知》（证监公司字[2007]128号）第五条相关标准的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal statement from Dongxing Securities regarding the stock price volatility of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It references regulatory notice 128 from 2007 concerning disclosure and insider trading rules. The document discusses stock price movements, compliance with regulatory standards, risk warnings, and the status of an ongoing major asset restructuring. It does not contain financial statements or detailed financial data but rather a regulatory compliance and risk disclosure related to stock price behavior and potential insider trading investigations. The document length is short (1370 characters) and is essentially a regulatory compliance announcement related to stock price movement and insider trading risk. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance disclosure and does not qualify as a full financial report, earnings release, or other specific report types.
2018-01-04 Chinese
东兴证券股份有限公司关于公司本次交易产业政策和交易类型之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor's Verification Opinion" related to a major asset restructuring transaction involving issuance of shares and capital raising. It references regulatory frameworks from the China Securities Regulatory Commission and Shanghai Stock Exchange concerning mergers and acquisitions. The content includes detailed verification of industry classification, transaction type, issuance of shares, and compliance with regulatory requirements. It is a formal advisory opinion rather than a full financial report or earnings release. The document length is 3087 characters, which is relatively short but contains substantive advisory content rather than just an announcement. This type of document fits best under the category of Capital/Financing Update (CAP) because it deals with issuance of shares, capital raising, and transaction verification related to financing activities.
2018-01-04 Chinese
关于公司前次募集资金使用情况的鉴证报告
Regulatory Filings
2018-01-04 Chinese
北京国枫律师事务所关于公司发行股份购买资产并募集配套资金暨关联交易的法律意见书
Regulatory Filings
2018-01-04 Chinese
上海傲源医疗用品有限公司审计报告
Regulatory Filings
2018-01-04 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.